The 7 most recent market catalysts affecting $HCAT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 21, 2026
Corporate Catalyst
Bearish
Impact 65
Canaccord Genuity Downgrades Health Catalyst to Hold, Lowers Price Target to $1.8
Canaccord Genuity analyst Richard Close downgraded Health Catalyst (HCAT) from a 'Buy' to a 'Hold' rating and slashed the price target from $3 to $1.8. This significant reduction i…
Aug 11, 2026
Corporate Catalyst
Bearish
Impact 55
Citigroup Maintains Neutral on Health Catalyst, Lowers Price Target to $2
Citigroup analyst Daniel Grosslight has maintained a 'Neutral' rating on Health Catalyst (HCAT) but lowered the price target from $2.50 to $2.00. This action indicates that while t…
Aug 7, 2026
Corporate Catalyst
Bearish
Impact 85
Health Catalyst shares are trading lower after the company issued Q3 sales and FY2026 sales guidance below estimates.
This headline represents a significant corporate catalyst, directly impacting Health Catalyst (HCAT) due to its disappointing sales guidance. The lower Q3 and FY2026 sales estimate…
Aug 7, 2026
Corporate Catalyst
Bearish
Impact 95
Health Catalyst Shares Tumble Overnight: What Investors Need to Know
Health Catalyst reported Q2 revenue that exceeded its own guidance and strengthened its balance sheet by repaying debt. However, the positive news was completely overshadowed by a …
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 85
Health Catalyst shares are trading lower after the company issued Q3 sales and FY2026 sales guidance below estimates.
The lower sales guidance from Health Catalyst (HCAT) is a direct negative catalyst, signaling that the company's revenue growth is not meeting prior expectations. This could be due…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 75
Health Catalyst Q2 Adj. EPS $0.04 Beats $0.03 Estimate, Sales $70.487M Beat $69.059M Estimate
Health Catalyst's Q2 earnings report shows a mixed picture. While the company surpassed analyst expectations for both adjusted EPS and sales, the significant 12.68% year-over-year …
Jul 21, 2026
Corporate Catalyst
Bullish
Impact 55
Canaccord Genuity Maintains Buy on Health Catalyst, Raises Price Target to $3
Canaccord Genuity analyst Richard Close maintained a 'Buy' rating on Health Catalyst (HCAT) and raised the price target from $2 to $3. This action signals increased confidence from…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.